Shandong Boan Biotechnology (HKG:6955) said China's Center for Drug Evaluation has accepted its investigational new drug (IND) application for BA2201.
BA2201 is a long-acting bispecific antibody being developed to treat inflammatory bowel disease, including Crohn's disease and ulcerative colitis, according to a Wednesday Hong Kong bourse filing.